This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Lowe, G. Search for Related Content Social Bookmarking                         What's this?

Review: Which patients with diabetes should receive which antiplatelet agents?

University Department of Medicine, Royal Infirmary, Glasgow, G31 2ER, UK, gdl1j{at}clinmed.gla.ac.uk

Patients with diabetes mellitus tend to have activated blood platelets, and increased circulating levels of co-factors (fibrinogen, von Willebrand factor) which promote platelet adhesion, aggregation and thrombosis. Systematic reviews of randomised controlled trials of antiplatelet agents show that antiplatelet agents reduce the risk of serious vascular events (myocardial infarction, stroke or death) by about one-quarter in patients with symptomatic vascular disease (secondary prevention), including those with diabetes. So, secondary prevention with an antiplatelet agent (aspirin, clopidogrel, or dipyridamole) should be considered in all diabetic patients with symptomatic vascular disease. Systematic reviews of randomised controlled trials of aspirin in primary prevention show a similar proportional reduction in coronary heart disease events, but not in stroke or death. The excess of adverse events for aspirin (haemorrhagic stroke, major gastrointestinal bleeds), which is unrelated to risk of cardiovascular disease, results in a lower risk: benefit ratio in primary prevention, and is also less cost-effective when aspirin is prescribed. Current SIGN guidelines recommend that aspirin be considered for primary prevention of coronary heart disease in diabetic or non-diabetic persons whose coronary risk is formally estimated to be 2% per year (in practice, over 80% of diabetic adults without symptomatic vascular disease). Discussions between clinicians and patients should address the potential benefits and harms of aspirin in primary prevention, as well as patient preferences. Further trials are required to identify subgroups in whom primary prevention is most beneficial.

Key Words: diabetes • platelets • coronary heart disease • aspirin.

The British Journal of Diabetes & Vascular Disease, Vol. 2, No. 3, 157-160 (2002)
DOI: 10.1177/14746514020020030201


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				S. Kennedy Comparing audits of cardiovascular risk in patients with diabetes in primary care The British Journal of Diabetes & Vascular Disease, July 1, 2003; 3(4): 295 - 299. [Abstract] [PDF]